David P. Brooks, Vice President Biology U.S., Cardiovascular and Urogenital Drug Discovery Centre, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania
"Development of non-peptide oxytocin receptor antagonists for the treatment of preterm labor."
Brooks is participating in a symposium, "Clinical utility of NH receptor analogs," chaired by Joseph Verbalis of Georgetown University and Maurice Manning of the Medical College of Ohio.
The other participants in the symposium are:
Robert H. Ring, head of molecular neurobiology, depression & anxiety disorders, discovery Neuroscience, Wyeth Research, Princeton, New Jersey.
"The central vasopressinergic and oxytocinergic systems as targets for psychiatric drug development."
Patrice Collins, Medical Affairs, Astellas Pharmaceuticals Inc.
"Effects of a novel vasopressin V1a/V2 antagonist conivaptin on serum sodium concentration and effective water clearance in hyponatremia clinical trials."
'"/>
19-Jul-2005